Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519318-30-00

Acronym

2020/ABM/01/00107

Enrollment

Registered

2025-03-27

Start date

2025-06-25

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-Hodgkin Lymphomas Subtypes: DLBCL - ORPHA: 544 Agressive B-cell non-Hodgkin lymphoma ORPHA: 300846 High grade B-cell lymphoma with MYCand/or BCL2 and/or BCL6 rearrangement ORPHA: 480541

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Poland

Outcome results